Liver metastases in prostate carcinoma: Clinical characteristics and outcome

BJU International

Volumn 99, Issue 4, 2007, Pages 807-811

  Pouessel, Damien ^a   Gallet, Blandine ^a   Bibeau, Frédéric ^a   Avancès, Christophe ^b   Iborra, François ^c   Sénesse, Pierre ^a   Culine, Stéphane ^a  

^a CENTRE VAL D AURELLE   (France)

^b Clinique Kennedy   (France)

^c Clinique du Parc   (France)

Author keywords

Liver metastases; Neuroendocrine differentiation; Prostate cancer

Indexed keywords

CARBOPLATIN; CHROMOGRANIN A; CISPLATIN; DOCETAXEL; DOXORUBICIN; ENOLASE; ESTRAMUSTINE PHOSPHATE; ESTROGEN; ETOPOSIDE; GONADORELIN AGONIST; MITOXANTRONE;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CARCINOMA, NEUROENDOCRINE; CHROMOGRANIN A; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33947305782     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06663.x     Document Type: Article

References (17)

1. Bumpus HC. Carcinoma of the prostate: a clinical study of one thousand cases. Surg Gynecol Obst 1926; 43: 150-5
2. Mintz R, Smith GG. Autopsy findings in 100 cases of prostatic cancer. N Eng J Med 1934; 11: 481-7
3. Rana A, Chisholm GD, Khan M, Sekharjit SS, Merrick MV, Elton RA. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br J Urol 1993; 72: 933-6
4. Shah RB, Mehra R, Chinnaiyan AM et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64: 9209-16
5. Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma. The M.D. Anderson Cancer Center experience. Cancer 2003; 98: 363-8
6. Fabozzi SJ, Schellhammer PF, el-Mahdi AM. Pulmonary metastases from prostate cancer. Cancer 1995; 75: 2706-9
7. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000; 31: 578-83
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer. Cancer 1981; 47: 207-14
9. Avances C, Jacot W, Senesse P, Culine S. Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer. J Urol 2002; 168: 1496
10. De la Monte SM, Moore GW, Hutchins GM. Metastatic behaviour of prostate cancer. Cluster analysis of patterns with respect to oestrogen treatment. Cancer 1986; 58: 985-93
11. Lamothe F, Kovi J, Heshmat MY, Green EJ. Dissemination of prostatic carcinoma: an autopsy study. J Natl Med Assoc 1986; 78: 1083-6
12. Roudier MP, True LD, Higano CS et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003; 34: 646-53
13. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
14. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
15. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47: 147-55
16. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod O, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997; 30: 1-6
17. Berruti A, Dogliotti L, Mosca A et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88: 2590-7